Sugi Predict

Sugi Predict / Compounds / SCHEMBL1596825

SCHEMBL1596825

SCHEMBL1596825

CCC(OC1C(O)[C@H](CO)O[C@@H]1n1cc(C)c(=O)n(COCc2ccccc2)c1=O)S(=O)(=O)O.[NaH]

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.35
▸ TK2 O00142 3/20 0.34
▸ LGALS3 P17931 1/20 0.34
▸ SLC5A2 P31639 2/20 0.33
▸ LGALS8 O00214 1/20 0.33
▸ SLC29A1 Q99808 1/20 0.32
▸ SLC6A2 P23975 1/20 0.31
▸ P2RY6 Q15077 1/20 0.31
▸ SLC5A1 P13866 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7962505 0.91 CYP1A2 (0.36) CYP1A2TK2LGALS3SLC5A2LGALS8
SCHEMBL5977733 0.83 SLC29A1 (0.44) CYP1A2SLC5A2SLC29A1P2RY6SLC5A1
SCHEMBL4660487 0.83 SLC29A1 (0.44) CYP1A2SLC5A2SLC29A1P2RY6SLC5A1
SCHEMBL5979165 0.80 CYP1A2 (0.38) CYP1A2TK2LGALS3LGALS8SLC29A1
SCHEMBL5979168 0.80 CYP1A2 (0.38) CYP1A2TK2LGALS3LGALS8SLC29A1
SCHEMBL14827428 0.76 PDE4D (0.34) CYP1A2TK2LGALS3P2RY6
SCHEMBL5979221 0.75 MEN1 (0.36) CYP1A2LGALS3
SCHEMBL5979226 0.75 MEN1 (0.36) CYP1A2LGALS3
SCHEMBL12718329 0.74 CYP1A2 (0.45) CYP1A2SLC5A2SLC29A1P2RY6
SCHEMBL14924494 0.74 ALDH1A1 (0.32) LGALS3P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200276222-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS IONIS PHARMACEUTICALS, INC. (US) 2020-09-03 — — US disclosed
US-10478449-B2 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations IONIS PHARMACEUTICALS, INC. (US) 2019-11-19 — — US disclosed
US-20180200282-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS IONIS PHARMACEUTICALS, INC. (US) 2018-07-19 — — US disclosed
US-20180104271-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS IONIS PHARMACEUTICALS, INC. (US) 2018-04-19 — — US disclosed
US-20180104272-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS IONIS PHARMACEUTICALS, INC. (US) 2018-04-19 — — US disclosed
US-9943539-B1 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations IONIS PHARMACEUTICALS, INC. (US) 2018-04-17 — — US disclosed
US-9943538-B1 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations IONIS PHARMACEUTICALS, INC. (US) 2018-04-17 — — US disclosed
US-20180028555-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS IONIS PHARMACEUTICALS, INC. (US) 2018-02-01 — — US disclosed
US-9827263-B2 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations IONIS PHARMACEUTICALS, INC. (US) 2017-11-28 — — US disclosed
US-20150366894-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS ISIS PHARMACEUTICALS, INC. (US) 2015-12-24 — — US disclosed
US-20040171033-A1 2'-substituted oligomeric compounds and compositions for use in gene modulations ISIS PHARMACEUTICALS, INC. 2004-09-02 — — US disclosed
US-20040171029-A1 2'-Fluoro substituted oligomeric compounds and compositions for use in gene modulations ISIS PHARMACEUTICALS, INC. 2004-09-02 — — US disclosed
US-20040161777-A1 Nucleotide sequences comprising terminal caps and inverted 3'-3' linkage for use in gene expression inhibition and preventing disease ISIS PHARMACEUTICALS, INC. 2004-08-19 — — US disclosed
US-20040147022-A1 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations ISIS PHARMACEUTICALS, INC. 2004-07-29 — — US disclosed
WO-2004044133-A2 MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed
WO-2004044132-A2 MODIFIED OLIGONUCLEOTIDES FOR USE IN RNA INTERFERENCE ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed
WO-2004043977-A2 2’-FLUORO SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed
WO-2004043978-A2 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS ISIS PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed
WO-2004044140-A2 2’-SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS ISIS PHARMACETICALS, INC. (US) 2004-05-27 — — WO disclosed
US-6277982-B1 REACTING CARBOHYDRATE, OLIGONUCLEOTIDE, NUCLEOTIDE OR NUCLEOSIDE WITH CYCLIC SULFATE; PRODUCTION OF OLIGONUCLEOTIDES WITH IMPROVED HYBRIDIZATION AFFINITY AND NUCLEASE RESISTANCE ISIS PHARMACEUTICALS, INC. 2001-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200276222-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS NSUN2, SNRPE, RBM3 CYP1A2 4815/4885TK2 2210/4885LGALS3 1957/4885
US-20180200282-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS NSUN2, SNRPE, RBM3 CYP1A2 4815/4885TK2 2210/4885LGALS3 1957/4885
US-10478449-B2 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations NSUN2, SNRPE, RBM3 CYP1A2 4824/4885TK2 2209/4885LGALS3 1992/4885
US-20040171029-A1 2'-Fluoro substituted oligomeric compounds and compositions for use in gene modulations NSUN2, HNRNPC, AGO2 CYP1A2 4853/4885TK2 1901/4885LGALS3 2255/4885
US-20150366894-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS NSUN2, SNRPE, RBM3 CYP1A2 4815/4885TK2 2210/4885LGALS3 1957/4885
US-20180028555-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS NSUN2, SNRPE, RBM3 CYP1A2 4815/4885TK2 2210/4885LGALS3 1957/4885
US-20040171033-A1 2'-substituted oligomeric compounds and compositions for use in gene modulations NSUN2, HNRNPC, SNRPE CYP1A2 4864/4885TK2 1917/4885LGALS3 2494/4885
US-20180104272-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS NSUN2, SNRPE, RBM3 CYP1A2 4815/4885TK2 2210/4885LGALS3 1957/4885
US-20040161777-A1 Nucleotide sequences comprising terminal caps and inverted 3'-3' linkage for use in gene expression inhibition and preventing disease RNGTT, RNMT, NUDT21 CYP1A2 4870/4885TK2 1386/4885LGALS3 3040/4885
US-20180104271-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS NSUN2, SNRPE, RBM3 CYP1A2 4815/4885TK2 2210/4885LGALS3 1957/4885
US-20040147022-A1 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations NSUN2, SNRPE, HNRNPC CYP1A2 4823/4885TK2 2206/4885LGALS3 2067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.